Accelerated (Intensive) Cardiac Training for Heart Failure Patients (ACT-HF)
Accelerated (Intensive) Cardiac Training for Heart Failure Patients (ACT-HF)
The purpose of this study is to see if patients undergoing accelerated Intensive Cardiac Rehabilitation (ICR) (2 weeks after discharge) will improve exercise performance as well as on measures of quality of life after a cardiac hospitalization.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The goal of this study is to evaluate the safety and effectiveness of initiating ICR (Intensive Cardiac Rehabilitation) at 2 weeks versus 6 weeks following hospital discharge in patients with HFrEF (Heart Failure with reduced Ejection Fraction). This is a randomized, controlled trial with two parallel groups. The Early Intervention Group with ICR initiated 2 weeks ±2 weeks following hospital discharge and the Usual Care Group with ICR initiated 6 weeks ±2 weeks after hospital discharge. Potential participants will be identified at Missouri Baptist Medical Center and referred for ICR at the HCI (Heart Care Institute) at Barnes Jewish West County Hospital (BJWCH). This study is being funded by the Missouri Baptist Healthcare Foundation.
To be evaluable, participants must complete a minimum of 24 ICR days, scheduled up to three days per week, with the option of completing a maximum of 36 ICR days over a period of up to 12-to-15-weeks post hospital discharge. The study team will analyze the ICR data from the start of ICR through 24 days of ICR. Data after 24 days will only include information on whether a participant continues to complete the maximum 36 days of ICR. During the trial, participants will complete performance tests and PRO (Participant Reported Outcome) surveys and questionnaires. Performance tests include a 6MWT (six minute walk test), a SPPB test (Short Performance Battery Test), and a handgrip test and will be completed at baseline, and the start of ICR and at the end of the completion of the 24th day of ICR.
PROs include a Cardiac Self-Efficacy Questionnaire (survey), Dartmouth COOP General Health Questionnaire (survey), PHQ-9 (survey), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Beck Depression Score (BDS), Rate Your Plate (RYP) and Duke Activity Status Index (DASI). PROs will be completed during baseline, start of ICR, and at the end of the 24th day of ICR.
The Early Intervention Group will repeat performance assessments and PROs 6-weeks (approximately 4-weeks post ICR start-up) following hospital discharge.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Dawson Haley A Haley, B.S.
- Número de teléfono: 314-362-8941
- Correo electrónico: dhaley@wustl.edu
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥ 18 years of age at the time of consent
- Diagnosis of HFrEF
- EF <35% within 3 months of hospital discharge
- Current hospitalization for a cardiac event (an approved cardiac diagnosis, such as chronic angina, recent MI (heart attack), cardiac surgery, or recent percutaneous coronary intervention (PCI) e.g., stent placement)
- Agreeable to complete 24 days of ICR and study requirements
- Ability and willingness to sign the ICF
- Referred to intensive cardiac rehabilitation at Washington University Heart Care Institute (HCI) at Barnes-Jewish West County Hospital (BJWCH).
Exclusion Criteria:
- Diagnosis of dementia
- Significant orthopedic limitations (e.g., double amputee) (walking with a walker is acceptable)
- Discharge to rehab facility or nursing home
- Pregnant women
- Currently enrolled in Hospice, not expected to live for 12 months
- Undergoing treatment for any type of cancer other than skin cancer
- History or evidence of any other clinically significant condition that, in the opinion of the investigator, might pose a safety risk to participants or interfere with study procedures, evaluation, or completion.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: 2 weeks post discharge group
Participants will be randomized into a 2 week post discharge group that will start cardiac rehabilitation 2 weeks after discharge compared to normal SOC at 6 weeks post discharge. |
Patients will be early referred (2 wks vs 6wks) to cardiac rehabilitation to see if there are benefits to early referral. |
|
Comparador de placebos: 6 weeks post discharge group (SOC)
Participants will be randomized into the SOC 6 week post discharge group. |
Normal Standard of care 6 week referral time. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety and Tolerability of Accelerated ICR 2 weeks and 6 weeks post-hospital discharge
Periodo de tiempo: From enrollment, to completion of at least 24 cardiac rehabilitation days.
|
To evaluate safety/tolerability of accelerated ICR beginning 2 weeks post-hospital discharge compared to usual standard care ICR beginning 6 weeks post-hospital discharge in patients with HFrEF. Safety will be determined by incidence of adverse events from randomization through 24 days after ICR initiation. Tolerability will be measured by number of ICR days attended (out of the required 24 ICR days). |
From enrollment, to completion of at least 24 cardiac rehabilitation days.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Efficacy of enrollment rates in Cardiac Rehabilitation
Periodo de tiempo: From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
To evaluate efficacy of early ICR (2 weeks post-hospital discharge) compared to usual care ICR (6 weeks post-hospital discharge) in patients with HFrEF. Efficacy and tolerability will be assessed from baseline through completion of 24 ICR days: • Changes in exercise performance in six minute walk test. |
From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
|
Efficacy of enrollment rates in Cardiac Rehabilitation
Periodo de tiempo: From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
To evaluate efficacy of early ICR (2 weeks post-hospital discharge) compared to usual care ICR (6 weeks post-hospital discharge) in patients with HFrEF. Efficacy and tolerability will be assessed from baseline through completion of 24 ICR days: • Changes in exercise performance in Short Performance Battery Test. |
From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
|
Efficacy of enrollment rates in Cardiac Rehabilitation
Periodo de tiempo: From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
To evaluate efficacy of early ICR (2 weeks post-hospital discharge) compared to usual care ICR (6 weeks post-hospital discharge) in patients with HFrEF. Efficacy and tolerability will be assessed from baseline through completion of 24 ICR days: • Changes in exercise performance in handgrip dynamometer test. |
From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
|
Efficacy of enrollment rates in Cardiac Rehabilitation
Periodo de tiempo: From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
To evaluate efficacy of early ICR (2 weeks post-hospital discharge) compared to usual care ICR (6 weeks post-hospital discharge) in patients with HFrEF. Efficacy and tolerability will be assessed from baseline through completion of 24 ICR days: • Changes in Patient Reported Outcomes (PROs): Cardiac Self-Efficacy Questionnaire. |
From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
|
Efficacy of enrollment rates in Cardiac Rehabilitation
Periodo de tiempo: From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
To evaluate efficacy of early ICR (2 weeks post-hospital discharge) compared to usual care ICR (6 weeks post-hospital discharge) in patients with HFrEF. Efficacy and tolerability will be assessed from baseline through completion of 24 ICR days: • Changes in Patient Reported Outcomes (PROs): Dartmouth COOP General Health Questionnaire |
From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
|
Efficacy of enrollment rates in Cardiac Rehabilitation
Periodo de tiempo: From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
To evaluate efficacy of early ICR (2 weeks post-hospital discharge) compared to usual care ICR (6 weeks post-hospital discharge) in patients with HFrEF. Efficacy and tolerability will be assessed from baseline through completion of 24 ICR days: • Changes in Patient Reported Outcomes (PROs): Minnesota Living with Heart Failure Questionnaire (MLHFQ) |
From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
|
Efficacy of enrollment rates in Cardiac Rehabilitation
Periodo de tiempo: From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
To evaluate efficacy of early ICR (2 weeks post-hospital discharge) compared to usual care ICR (6 weeks post-hospital discharge) in patients with HFrEF. Efficacy and tolerability will be assessed from baseline through completion of 24 ICR days: • Changes in Patient Reported Outcomes (PROs): Beck Depression Score (BDS) |
From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
|
Efficacy of enrollment rates in Cardiac Rehabilitation
Periodo de tiempo: From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
To evaluate efficacy of early ICR (2 weeks post-hospital discharge) compared to usual care ICR (6 weeks post-hospital discharge) in patients with HFrEF. Efficacy and tolerability will be assessed from baseline through completion of 24 ICR days: • Changes in Patient Reported Outcomes (PROs): Rate Your Plate (RYP) |
From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
|
Efficacy of enrollment rates in Cardiac Rehabilitation
Periodo de tiempo: From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
To evaluate efficacy of early ICR (2 weeks post-hospital discharge) compared to usual care ICR (6 weeks post-hospital discharge) in patients with HFrEF. Efficacy and tolerability will be assessed from baseline through completion of 24 ICR days: • Changes in Patient Reported Outcomes (PROs): Duke Activity Status Index (DASI) |
From enrollment, to at least the completion of 24 cardiac rehabilitation days.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Rehospitalization and All- Cause Morality within 6 Months Post-Hospital Discharge
Periodo de tiempo: Enrollment to within 6 months post-hospital discharge
|
To evaluate rehospitalization and all-cause mortality within 6 months post-hospital discharge for HFrEF patients enrolled in early ICR (2 weeks post-hospital discharge) compared to usual care ICR (6 weeks post-hospital discharge).I ncidence of rehospitalization and, all-cause mortality and deaths from randomization through the 6-month follow up phone call. |
Enrollment to within 6 months post-hospital discharge
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Linda R Peterson, M.D., Washington University School of Medicine
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 202603003
- GR0041819 (Otro número de subvención/financiamiento: Missouri Baptist Healthcare Foundation)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .